IER3 and Hodgkins lymphoma: The next step would be to understand better the cause of increased IER3 expression in AEZS-136-resistant HL to identify the optimal combination therapy, including therapies that would induce apoptosis irrespective of IER3 levels (cisplatin, gemcitabine, or doxorubicin) or that would increase ROS levels57.